Niemann-Pick B - RS - 5th infusion.
Por um escritor misterioso
Descrição
Niemann-Pick Disease
Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults, Orphanet Journal of Rare Diseases
Necroptosis in Niemann–Pick disease, type C1: a potential therapeutic target
PDF) Consensus clinical management guidelines for Acid Sphingomyelinase Deficiency (Niemann-Pick disease types A, B and A/B)
PDF) A Prospective, Cross-sectional Survey Study of the Natural History of Niemann-Pick Disease Type B
IJMS, Free Full-Text
Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults, Orphanet Journal of Rare Diseases
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms
WO2022026410A2 - Compositions and methods for the treatment of niemann-pick type c1 disease - Google Patents
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet
Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
